Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C

Canbakan M.a · Senturk H.b · Canbakan B.b · Toptas T.f · Tabak O.g · Ozaras R.d · Tabak F.d · Balcı H.c · Sut N.h · Ozbay G.e

Author affiliations

aDepartment of Nephrology, Haydarpasa Numune Training and Research Hospital, bDepartment of Gastroenterology, cFikret Biyal Central Research Laboratory, dDepartment of Infectious Diseases and Clinical Microbiology, and eDepartment of Pathology, Cerrahpasa Medical Faculty of Istanbul University, fDivision of Hematology, Marmara University Hospital, gDepartment of Internal Medicine, Istanbul Training and Research Hospital, Istanbul, and hDepartment of Biostatistics and Medical Informatics, Trakya University Medical Faculty, Edirne, Turkey

Related Articles for ""

Nephron Clin Pract 2011;117:c289–c295

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 09, 2010
Accepted: June 04, 2010
Published online: September 18, 2010
Issue release date: February 2011

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC

Abstract

Background: Liver biopsy is an imperfect gold standard for assessing the disease severity in hemodialysis patients with chronic hepatitis C. Our purpose was to compare the accuracy of the FibroTest (FT) and ActiTest (AT) with liver biopsy and the AST-to-platelet ratio index (APRI) in determining hepatic fibrosis and necroinflammatory activity in hemodialysis patients with hepatitis C virus (HCV). Methods: The FT-AT index combining 6 biochemical markers was assessed in 33 hemodialysis patients with HCV. Liver fibrosis and necroinflammatory activity was staged and graded according to the METAVIR scoring system. Results: The accuracy of FT-AT versus biopsy was 0.46 for significant fibrosis and 0.36 for severe necroinflammatory activity. The FT index had a positive predictive value of 20% for scores greater than 0.6 and a negative predictive value of 45% for scores less than 0.2. Eleven of the 33 patients had scores ≤0.2, 6 had significant fibrosis on biopsy. Four out of 5 patients with FT scores >0.6 had mild fibrosis. APRI correlated well with the biopsy. Conclusion: The FT-AT test does not seem to be a reliable noninvasive marker for the prediction of necroinflammatory activity and fibrosis in hemodialysis patients with HCV and cannot be used as an alternative to either liver biopsy or APRI.

© 2010 S. Karger AG, Basel


References

  1. Poux JM, Cadranel JF, Fievet P, Dumouchel P, Collot G: Measurement of gamma glutamyl transpeptidase activity: a useful and low-cost tool for the detection of HCV infection in haemodialysed patients. Nephrol Dial Transplant 1998;13:1324.
  2. Pereira BJ, Levey AS: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981–999.
  3. Rostaing L, Izopet J, Arnaud C, Cisterne JM, Alric L, Rumeau JL, Duffaut M, Durand D: Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Transplantation 1999;67:556–560.
  4. Hanafusa T, Ichikawa Y, Yazawa K, Kishikawa H, Fukunishi T, Kanai T, Shinji Y, Nagano S: Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc 1998;30:122–124.
  5. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813–828.
  6. EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 1999;31 (Suppl 1):3–8.
    External Resources
  7. Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology 1997;26(Suppl 1):57S–61S.
    External Resources
  8. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S: Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 2005;80:1550–1555.
  9. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–1075.
  10. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–526.
  11. Szasz G, Persinj JP, van der Slik W: A new method for the determination of γ-glutamyl transferase. J Clin Chem Biochem 1976;14:421–427.
    External Resources
  12. Bergmeyer HU, Horder M, Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Biochem 1986;24:481–489.
  13. Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P, Lo KJ: Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994;9:587–591.
  14. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093–1102.
  15. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–293.
  16. Roth D: Hepatitis C virus: the nephrologist’s view. Am J Kidney Dis 1995;25:3–16.
  17. Pol S: Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. Adv Nephrol Necker Hosp 1995;24:315–330.
  18. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990;99:1396–1400.
  19. Perrault J, McGill DB, Ott BJ, Taylor WF: Liver biopsy: complications in 1,000 inpatients and outpatients. Gastroenterology 1978;74:103–106.
  20. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32:477–481.
  21. Navarro J, Contreras P, Touraine JL, Freyria AM, Later R, Traeger J: Are ‘middle molecules’ responsible for toxic phenomena in chronic renal failure? Nephron 1982;32:301–307.
  22. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;23:8.
    External Resources
  23. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D: Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006;101:547–555.
  24. Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C: Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C. Gastroenterol Clin Biol 2008;32:858–865.
  25. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P, PANFIBROSIS Group: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257–265.
  26. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V: Biomarkers of liver fibrosis. Adv Clin Chem 2008;46:131–160.
  27. Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC, Association francaise pour l’etude du foie; Club de reflexion des cabinets et groupes d’hepato-gastro-enterologue; College national des generalistes enseignants; Groupe francophone d’hepatologie gastro-enterologie et nutrition pediatriques; Societe francaise de biologie clinique; Societe francaise de radiologie; Societe nationale francaise de gastro-enterologie: Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007;31:504–509.
  28. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–1075.
  29. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T: Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003;17:721–725.
  30. Kamanna VS, Kashyap ML, Pai R, Bui DT, Jin FY, Roh DD, Shah GM, Kirschenbaum MA: Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994;5:193–200.
  31. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F, GERMED cyt04 Group: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128–133.
  32. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH: Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 1993;17:364–369.
  33. Trznadel K, Luciak M, Paradowski M, Kubasiewicz-Ujma B: Hemodialysis and the acute-phase response in chronic uremic patients. Int J Artif Organs 1989;12:762–765.
  34. Argilés A, Kerr PG, Mourad G, Mion CM, Atkins RC: Serum alpha 2-macroglobulin in haemodialysis patients: baseline and kinetic studies. Nephrol Dial Transplant 1993;8:1118–1123.
    External Resources
  35. Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-Meir S, Martinowitz U, Halfon P: Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007;13:722–729.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 09, 2010
Accepted: June 04, 2010
Published online: September 18, 2010
Issue release date: February 2011

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2


eISSN: 1660-2110 (Online)

For additional information: https://www.karger.com/NEC


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.